Lunit: European Journal of Radiology Publishes Study Highlighting 77% Reduction in Triage Time Lunit announced on Dec. 26 that a study demonstrating the significant reduction in time required for emergency patient triage using their AI...

Lunit and Volpara revealed a unified Ecosystem at RSNA 2024, featuring AI-powered cancer risk prediction, autonomous report generation, and innovations to transform global cancer care SEOUL, South Korea, Dec. 5, 2024 /PRNewswire/ -- At...

Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pathology platform to enhance precision medicine and improve cancer biomarker testing SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Lunit...

Lunit: A new study published in the Journal for ImmunoTherapy of Cancer (JITC) shows that Lunit's AI-powered biomarker "Lunit SCOPE IO" can predict favorable outcomes of Inflamed Immune Phenotype patients treated with Immune Checkpoint...

South Korean biotech company GC Cell Corp. said Thursday that it signed a joint research and supply agreement with medical artificial intelligence (AI) company Lunit Inc. for new drug candidate AB-201. Under the agreement, GC Cell will conduct...

Lunit INSIGHT DBT receives FDA 510(k) clearance, poised to enter the world's largest DBT market SEOUL, South Korea, Nov. 14, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics...